Apelin as a marker for monitoring the tumor vessel normalization window during antiangiogenic therapy

Cancer Science

Volumn 107, Issue 1, 2016, Pages 36-44

  Zhang, Li ^a   Takara, Kazuhiro ^a   Yamakawa, Daishi ^a   Kidoya, Hiroyasu ^a   Takakura, Nobuyuki ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Apelin; Hypoxia; Tumor; Vascular normalization

Indexed keywords

APELIN; BEVACIZUMAB; FLUOROURACIL; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; TUMOR MARKER; ANGIOGENESIS INHIBITOR; APLN PROTEIN, HUMAN; SIGNAL PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; CAPILLARY DENSITY; COLORECTAL CARCINOMA; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HT 29 CELL LINE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PERICYTE; PRIORITY JOURNAL; SINGLE DRUG DOSE; TUMOR CELL INOCULATION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; ADENOCARCINOMA; ANIMAL; CELL SEPARATION; COLON TUMOR; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; HT-29 CELL LINE; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; WESTERN BLOTTING;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; BEVACIZUMAB; BIOMARKERS, TUMOR; BLOTTING, WESTERN; CELL SEPARATION; COLONIC NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HT29 CELLS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; NEOVASCULARIZATION, PATHOLOGIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84956584062     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12836     Document Type: Article

References (54)

1. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972; 175: 409-16.
2. Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 2014; 26: 605-22.
3. Browder T, Butterfield CE, Kräling BM et al. Anti-angiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60: 1878-86.
4. Klement G, Baruchel S, Rak J et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000; 105: R15-24.
5. Kozin SV, Boucher Y, Hicklin DJ et al. VEGF receptor-2 blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res 2001; 61: 39-44.
6. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
7. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7: 987-9.
8. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62.
9. Goel S, Duda DG, Xu L et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011; 91: 1071-121.
10. Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol 2013; 31: 2205-18.
11. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473: 298-307.
12. Tatemoto K, Hosoya M, Habata Y et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998; 251: 471-6.
13. O'Dowd BF, Heiber M, Chan A et al. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 1993; 136: 355-60.
14. Berry MF, Pirolli TJ, Jayasankar V et al. Apelin has in vivo inotropic effects on normal and failing hearts. Circulation 2004; 110: II187-93.
15. Atluri P, Morine KJ, Liao GP et al. Ischemic heart failure enhances endogenous myocardial apelin and APJ receptor expression. Cell Mol Biol Lett 2007; 12: 127-38.
16. Ashley EA, Powers J, Chen M et al. The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc Res 2005; 65: 73-82.
17. Roberts EM, Newson MJ, Pope GR, Landgraf R, Lolait SJ, O'Carroll AM. Abnormal fluid homeostasis in apelin receptor knockout mice. J Endocrinol 2009; 202: 453-62.
18. Roberts EM, Pope GR, Newson MJ, Landgraf R, Lolait SJ, O'Carroll AM. Stimulus-specific neuroendocrine responses to osmotic stimuli in apelin receptor knockout mice. J Neuroendocrinol 2010; 22: 301-8.
19. Boucher J, Masri B, Daviaud D et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 2005; 146: 1764-71.
20. Dray C, Knauf C, Daviaud D et al. Apelin stimulates glucose utilization in normal and obese insulin-resistant mice. Cell Metab 2008; 8: 437-45.
21. Edinger AL, Hoffman TL, Sharron M et al. An orphan seven-transmembrane domain receptor expressed widely in the brain functions as a coreceptor for human immunodeficiency virus type 1 and simian immunodeficiency virus. J Virol 1998; 72: 7934-40.
22. Cox CM, D'Agostino SL, Miller MK, Heimark RL, Krieg PA. Apelin, the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo. Dev Biol 2006; 296: 177-89.
23. Kasai A, Shintani N, Oda M et al. Apelin is a novel angiogenic factor in retinal endothelial cells. Biochem Biophys Res Commun 2004; 325: 395-400.
24. Kasai A, Shintani N, Kato H et al. Retardation of retinal vascular development in apelindeficient mice. Arterioscler Thromb Vasc Biol 2008; 28: 1717-22.
25. Kidoya H, Naito H, Muramatsu F et al. APJ regulates parallel alignment of arteries and veins in the skin. Dev Cell 2015; 33: 247-59.
26. Kidoya H, Ueno M, Yamada Y et al. Spatial and temporal role of the apelin/APJ system in the caliber size regulation of blood vessels during angiogenesis. EMBO J 2008; 27: 522-34.
27. Kalin RE, Kretz MP, Meyer AM, Kispert A, Heppner FL, Brandli AW. Paracrine and autocrine mechanisms of apelin signaling govern embryonic and tumor angiogenesis. Dev Biol 2007; 305: 599-614.
28. Picault FX, Chaves-Almagro C, Projetti F, Prats H, Masri B, Audigier Y. Tumour co-expression of apelin and its receptor is the basis of an autocrine loop involved in the growth of colon adenocarcinomas. Eur J Cancer 2014; 50: 663-74.
29. Berta J, Kenessey I, Dobos J et al. Apelin expression in human non-small cell lung cancer: role in angiogenesis and prognosis. J Thorac Oncol 2010; 5: 1120-9.
30. Heo K, Kim YH, Sung HJ et al. Hypoxia-induced up-regulation of apelin is associated with a poor prognosis in oral squamous cell carcinoma patients. Oral Oncol 2012; 48: 500-6.
31. Wan Y, Zeng ZC, Xi M et al. Dysregulated microRNA-224/apelin axis associated with aggressive progression and poor prognosis in patients with prostate cancer. Hum Pathol 2015; 46: 295-303.
32. Muto J, Shirabe K, Yoshizumi T et al. The apelin-APJ system induces tumor arteriogenesis in hepatocellular carcinoma. Anticancer Res 2014; 34: 5313-20.
33. Facciabene A, Peng X, Hagemann IS et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 2011; 475: 226-30.
34. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011; 11: 393-410.
35. Eyries M, Siegfried G, Ciumas M et al. Hypoxia-induced apelin expression regulates endothelial cell proliferation and regenerative angiogenesis. Circ Res 2008; 103: 432-40.
36. Winkler F, Kozin SV, Tong RT et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004; 6: 553-63.
37. Franco M, Man S, Chen L et al. Targeted antivascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res 2006; 66: 3639-48.
38. Datta M, Via LE, Kamoun WS et al. Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery. Proc Natl Acad Sci USA 2015; 112: 1827-32.
39. Wildiers H, Guetens G, De Boeck G et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 2003; 88: 1979-86.
40. Wong PP, Demircioglu F, Ghazaly E et al. Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread. Cancer Cell 2015; 27: 123-37.
41. Li XF, Carlin S, Urano M, Russell J, Ling CC, O'Donoghue JA. Visualization of hypoxia in microscopic tumors by immunofluorescent microscopy. Cancer Res 2007; 67: 7646-53.
42. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008; 8(8): 579-91.
43. Vangestel C, Van de Wiele C, Van Damme N et al. (99)mTc-(CO)(3) His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab. J Nucl Med 2011; 52: 1786-94.
44. Myers AL, Williams RF, Ng CY, Hartwich JE, Davidoff AM. Bevacizumab-induced tumor vessel remodeling in rhabdomyosarcoma xenografts increases the effectiveness of adjuvant ionizing radiation. J Pediatr Surg 2010; 45: 1080-5.
45. Dings RP, Loren M, Heun H et al. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res 2007; 13: 3395-402.
46. Dickson PV, Hamner JB, Sims TL et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 2007; 13: 3942-50.
47. Duda DG, Willett CG, Ancukiewicz M et al. Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. Oncologist 2010; 15: 577-83.
48. Mazzone M, Dettori D, Leite de Oliveira R et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 2009; 136: 839-51.
49. Nixon AB, Pang H, Starr MD et al. Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Clin Cancer Res 2013; 19: 6957-66.
50. Augustin HG, Koh GY, Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 2009; 10: 165-77.
51. del Toro R, Prahst C, Mathivet T et al. Identification and functional analysis of endothelial tip cell-enriched genes. Blood 2010; 116: 4025-33.
52. Heinonen MV, Purhonen AK, Miettinen P et al. Apelin, orexin-A and leptin plasma levels in morbid obesity and effect of gastric banding. Regul Pept 2005; 130: 7-13.
53. Chen MM, Ashley EA, Deng DX et al. Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation 2003; 108: 1432-9.
54. Chong KS, Gardner RS, Morton JJ, Ashley EA, McDonagh TA. Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur J Heart Fail 2006; 8: 355-60.